Novelix Pharmaceuticals Limited has made a regulatory disclosure to BSE Limited regarding the allotment of equity shares through warrant conversion.

The Board of Directors of the Company approved the allotment in a meeting held on 29th May, 2026 at the Registered Office of the company (H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana-500029). The meeting commenced at 5:00 PM and concluded at 6:30 PM.

The company allotted 28,10,000 equity shares of face value ₹10 each at an issue price of ₹20 per share (including a premium of ₹10 per share). These shares were allotted upon exercise of conversion option by warrant holders who had previously paid ₹15 per warrant (75% of the issue price).

These warrants were part of 1,50,00,000 warrants allotted on 10th January, 2025 on a preferential basis. The original warrant allotment was approved through a Special Resolution passed by shareholders at the Extra-Ordinary General Meeting on November 28th, 2024, with in-principle approval received from BSE Limited on December 31st, 2024.

Allottee Details

The allotment was made to 14 investors categorized as follows:

Strategic Investors (Promoter and Promoter Group):

  • SRINIDHI FINE-CHEMICALS LLP: 800,000 shares
  • NARAHARI BELIDE: 150,000 shares
  • VUPPARAPALLI CHANDRASEKHAR REDDY: 560,000 shares
  • GATTU GNANA PRAKASH: 50,000 shares
  • ARATI GATTU: 100,000 shares

Strategic Investors (Non-Promoters):

  • PALAKURTHI RAKESH: 300,000 shares
  • MANUSANI VENKAT RAMANA: 200,000 shares
  • BEJUGAM SUNIL KUMAR: 200,000 shares
  • R SHAILAJA: 150,000 shares
  • M. JALAJA LAXMI: 100,000 shares
  • KARUNAKAR MURIKI: 50,000 shares
  • BELIDE RAJENDER: 50,000 shares
  • BELIDE VIJAYALAXMI: 50,000 shares
  • THOTA MAHESH: 50,000 shares

Financial Impact

The company received ₹4,21,50,000.00 (Rupees Four Crores Twenty-One Lakhs Fifty Thousand) representing 75% of the issue price for the 28,10,000 equity shares.

Consequent to this allotment, the paid-up equity capital of the Company has increased from ₹210,850,000.00 (consisting of 21,085,000 Equity Shares of ₹10 each) to ₹238,950,000.00 (consisting of 23,895,000 Equity Shares of ₹10 each).

The disclosure is made pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015 read with SEBI Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.